Patents Assigned to AstraZeneca
  • 2-heteroaryl substituted benzothiophenes and benzofuranes 709
    Patent number: 7772256
    Abstract: The present invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: August 10, 2010
    Assignee: Astrazeneca AB
    Inventors: Erwan Arzel, Britt-Marie Swahn, David Wensbo
  • Oxabispidine compounds useful in the treatment of cardiac arrhythmias
    Patent number: 7772229
    Abstract: There is provided compounds of formula I, wherein R1, R2, R3, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: August 10, 2010
    Assignee: AstraZeneca AB
    Inventors: Annika Björe, Magnus Björsne, Kurt-Jürgen Hoffmann, Fritiof Pontėn, Gert Strandlund, Peder Svensson, Michael Wilsterman
  • mGluR5 modulators
    Patent number: 7772235
    Abstract: The present invention is directed to compounds of formula I: Wherein R1 to R5, X and Z are further defined in the description. The invention also relates to processes for the preparation of the compounds and to intermediates used in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: September 25, 2007
    Date of Patent: August 10, 2010
    Assignee: Astrazeneca AB
    Inventors: Methvin Isaac, Abdelmalik Slassi, Louise Edwards, Peter Dove, Tao Xin, Tomislav Stefanac
  • BLISTER PACK DEVICE AND A METHOD OF EJECTING A UNIT DOSAGE FROM A BLISTER PACK USING THE DEVICE
    Publication number: 20100193536
    Abstract: The present invention relates to a blister pack device for dispensing a dosage unit from a blister pack. The blister pack has at least one blister and a lid foil. The device comprises a first arm and a second lever arm hingedly connected to each other, the first arm comprises an aperture through which the dosage unit can be ejected. The lever arm comprises a protruding member for pressing out a dosage unit from the blister when the lever arm is lowered down onto the blister positioned on the first arm. The protruding member comprises a first section for applying a pressing force on the dosage unit inside the blister to initiate the breaking of the lid foil of the blister pack and a second section for distributing the pressing force over the dosage unit and for ejecting the dosage unit.
    Type: Application
    Filed: November 14, 2006
    Publication date: August 5, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Maria Benktzon, Sofia Jacobsson, Anders Löfgren, Thomas Nilsson, Ulrika Vejbrink
  • CHEMICAL COMPOUNDS
    Publication number: 20100197749
    Abstract: The invention relates to chemical compounds of formula (I) and (II): or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: January 15, 2007
    Publication date: August 5, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Scott Cowen, Tracey Deegan, Gurmit Grewal, Vibha Oza, Jamal Carlos Saeh, Qibin Su
  • HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20100190745
    Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Application
    Filed: June 3, 2009
    Publication date: July 29, 2010
    Applicant: AstraZeneca AB
    Inventors: Allison Laura Choy, Pamela Hill, John Irvin Manchester, Brian Sherer
  • Salts
    Patent number: 7763597
    Abstract: There is provided pharmaceutically-acceptable acid addition salts of compounds of formula (I), wherein R1 represents C1-2 alkyl substituted by one or more fluoro substituents; R2 represents C1-2 alkyl; and n represents 0, 1 or 2, which salts are useful as prodrugs of competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required.
    Type: Grant
    Filed: August 16, 2007
    Date of Patent: July 27, 2010
    Assignee: AstraZeneca AB
    Inventors: Matti Ahlqvist, Martin Bohlin, Tord Inghardt, Anita Lundblad, Carl-Gustaf Sigfridsson
  • CHEMICAL COMPOUNDS 553
    Publication number: 20100184813
    Abstract: DGAT-1 inhibitor compounds of formula (I) and pharmaceutically-acceptable salts thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein n is 0, 1, 2 or 3, R is independently selected from fluoro, chloro, bromo, trifluoromethyl, methoxy, difluoromethoxy and trifluoromethoxy and Z is carboxy or a mimic or bioisostere thereof, hydroxyl, hydroxymethyl, or —CONRbRc wherein Rb and Rc are independently selected from hydrogen and (1-4C)alkyl, which (1-4C)alkyl group may be optionally substituted by carboxy or a mimic or bioisostere thereof.
    Type: Application
    Filed: December 18, 2009
    Publication date: July 22, 2010
    Applicant: AstraZeneca AB
    Inventors: Alan Martin BIRCH, Gary Peter Tomkinson, Sharmistha Pal, Anna Pettersen
  • Uses of cinnoline compounds to treat schizophrenia
    Publication number: 20100184738
    Abstract: This invention relates to the use of compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions in treating schizophrenia.
    Type: Application
    Filed: March 15, 2010
    Publication date: July 22, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Jeffery Louis Arriza, Marc Chapdelaine, Edward Christian
  • Novel Process
    Publication number: 20100183729
    Abstract: The invention relates to a stable pharmaceutical composition useful in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD) and a novel micronisation process for manufacturing a stable formulation for formoterol or its enantiomers and a carrier/diluent comprising a carbohydrate such as lactose.
    Type: Application
    Filed: January 14, 2010
    Publication date: July 22, 2010
    Applicant: AstraZeneca AB
    Inventor: Eva Trofast
  • Composition for inhalation
    Patent number: 7759328
    Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: July 20, 2010
    Assignee: AstraZeneca AB
    Inventors: Nayna Govind, Maria Marlow
  • Ethanamine Compounds and Methods of Using the Same 545
    Publication number: 20100179199
    Abstract: The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.
    Type: Application
    Filed: December 22, 2009
    Publication date: July 15, 2010
    Applicant: AstraZeneca AB
    Inventors: Michael Balestra, Peter Bernstein, Glen E. Ernst, William Frietze, John P. McCauley, Lihong Shen, David Nugiel
  • PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS
    Publication number: 20100179161
    Abstract: Compounds of the formula (I) and pharmaceutically acceptable salts or in vivo hydrolysable esters thereof, useful in the treatment of Mycobacterium tuberculosis (M.tb).
    Type: Application
    Filed: August 16, 2006
    Publication date: July 15, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Balachandra Shankar Bandodkar, Stefan Schmitt
  • ANTIBACTERIAL PIPERDINE DERIVATIVES
    Publication number: 20100179150
    Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Application
    Filed: February 16, 2006
    Publication date: July 15, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Gregory Basarab, Brian Dangel, Paul Robert Fleming, Michael Barry Gravestock, Oluyinka Green, Sheila Irene Hauck, Pamela Hill, Kenneth Gregory Hull, George Mullen, Brian Sherer, Fei Zhou, Haihong Ni
  • Metalloproteinase inhibitors
    Patent number: 7754750
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: July 13, 2010
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Targeted binding agents directed to PDGFR-alpha and uses thereof
    Patent number: 7754859
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: July 13, 2010
    Assignee: AstraZeneca AB
    Inventors: Naomi Laing, Jaspal Singh Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, David Charles Blakey, Sue A. Cartlidge
  • Substituted indoles
    Patent number: 7754735
    Abstract: The present invention relates to substituted indoles of formula (I), useful as pharmaceutical compounds for treating respiratory disorders.
    Type: Grant
    Filed: May 27, 2003
    Date of Patent: July 13, 2010
    Assignee: AstraZeneca AB
    Inventors: Timothy Birkinshaw, Roger Bonnert, Tony Cook, Rukhsana Rasul, Hitesh Sanganee, Simon Teague
  • Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia
    Publication number: 20100173935
    Abstract: Compounds of Formula IA, or pharmaceutically acceptable salts thereof: IA wherein G1, G2, G3, G4, R1, R2, X, Y, Z and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: June 8, 2007
    Publication date: July 8, 2010
    Applicant: AstraZeneca AB
    Inventors: Yun-Xing Cheng, Shujuan Jin, Mehrnaz Pourashraf, Miroslaw Tomaszewski
  • Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia
    Publication number: 20100173941
    Abstract: Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, R5, R6, R7, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: June 8, 2007
    Publication date: July 8, 2010
    Applicant: AstraZeneca AB
    Inventors: Yun-Xing Cheng, Miroslaw Tomaszewski
  • Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease
    Publication number: 20100173890
    Abstract: The present invention relates to new compounds of formula I, or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in the treatment of 5-HT6 mediated disorders such as Alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and Parkinson's disease.
    Type: Application
    Filed: July 3, 2006
    Publication date: July 8, 2010
    Applicant: AstraZeneca AB
    Inventors: Gunnar Nordvall, Fernando Sehgelmeble